Mealey's IP/Tech - Federal Circuit Affirms: Hepatitis Drug Patent Is Invalid

Mealey's IP/Tech - Federal Circuit Affirms: Hepatitis Drug Patent Is Invalid

WASHINGTON, D.C. - A Delaware federal magistrate judge properly deemed a claim covering plaintiff Bristol-Myers Squibb (BMS) Co.'s patented hepatitis B entecavir drug "Baraclude" invalid, the Federal Circuit U.S. Court of Appeals concluded June 12 (Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA Inc., No. 13-1306, Fed. Cir.).

Find full version on lexis Advance®
Access this news story on lexis.com®